Department of Pharmacology, Celal Bayar University, Faculty of Medicine, Manisa, Turkey.
Swiss Med Wkly. 2012 Apr 5;142:w13558. doi: 10.4414/smw.2012.13558. eCollection 2012.
Impairment of the vasorelaxant responses have been reported in diabetes mellitus. In this study, the roles of the K(ATP) channel and rho kinase pathway were evaluated by using the K(ATP) channel opener cromakalim and Rho-kinase inhibitor HA 1077 in diabetic rat aorta.
Adult male Wistar rats weighing (250-300 g) were divided into diabetic and control groups. Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 55 mg/kg/i.p).
Vasodilator responses induced by cromakalim (10(-7) to 10(-3M)) and HA 1077 (10(-6) to 10(-4M)) were significantly less in diabetic rings compared with control rings (p <0.01). The decrease in the relaxant effect of cromakalim was more in endothelium-denuded rings compared to the endothelium-intact rings (p <0.05). There were no significant differences between endothelium intact and non-intact rings in the presence of HA 1077. When two drugs were administered together, relaxation was significantly less than with seperate administration of each drug in the diabetic group (p <0.01). Pre-treatment with N omega-nitro-L-arginine methylester (L-NAME) (10(-6) to 10(-4 M)), an NO synthase inhibitor, significantly decreased the relaxant response to cromakalime and HA 1077 in both the control and diabetic groups (p <0.05).
These results suggest that the impaired relaxant effects were further decreased depending on K(ATP) channel activity but the effects of Rho-kinase enzyme inhibitors on relaxation responses were not significantly changed in diabetes mellitus.
糖尿病患者的血管舒张反应受损已有报道。在这项研究中,通过使用 K(ATP)通道 opener cromakalim 和 Rho-kinase 抑制剂 HA 1077,评估了 K(ATP)通道和 rho 激酶途径在糖尿病大鼠主动脉中的作用。
成年雄性 Wistar 大鼠(体重 250-300g)分为糖尿病组和对照组。糖尿病通过单次腹腔注射链脲佐菌素(STZ,55mg/kg/i.p)诱导。
与对照组相比,糖尿病组的 cromakalim(10(-7) 至 10(-3M))和 HA 1077(10(-6) 至 10(-4M))诱导的血管舒张反应明显减弱(p <0.01)。与内皮完整环相比,去内皮环中 cromakalim 的舒张作用下降更明显(p <0.05)。在存在 HA 1077 的情况下,内皮完整和非完整环之间没有显著差异。当两种药物一起给药时,与单独给药相比,糖尿病组的松弛作用明显降低(p <0.01)。NO 合酶抑制剂 N omega-nitro-L-arginine methylester(L-NAME)(10(-6) 至 10(-4M))预处理显著降低了 cromakalime 和 HA 1077 在对照组和糖尿病组中的舒张反应(p <0.05)。
这些结果表明,在糖尿病中,依赖于 K(ATP)通道活性的舒张反应受损进一步降低,而 Rho-kinase 酶抑制剂对舒张反应的影响没有明显改变。